Core Points - I-Mab, a U.S.-based global biotech company, focuses on developing precision immuno-oncology agents for cancer treatment [2] - The management team of I-Mab will participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference on February 11-12, 2025 [1] - The conference will include a company presentation and one-on-one meetings, with I-Mab's presentation scheduled for February 11, 2025, from 4:00 to 4:30 PM ET [1] Company Overview - I-Mab is headquartered in Rockville, Maryland, and has operations in Short Hills, New Jersey [2] - The company specializes in precision immuno-oncology, targeting cancer treatment [2] Contact Information - Investor and media inquiries can be directed to PJ Kelleher at LifeSci Advisors [3] - Contact details include a phone number and email for investor relations [3]

Core Viewpoint - Cardiol Therapeutics Inc. is set to present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025, focusing on its clinical-stage anti-inflammatory and anti-fibrotic therapies for heart disease [1]. Company Overview - Cardiol Therapeutics Inc. is a clinical-stage life sciences company specializing in the research and development of therapies targeting inflammation and fibrosis in heart disease [3]. - The company's lead drug candidate, CardiolRx™ (cannabidiol) oral solution, is in clinical development and aims to inhibit the inflammasome pathway, which is crucial in the progression of inflammation and fibrosis related to heart conditions [3]. Clinical Development - Cardiol has received Investigational New Drug Application authorization from the US FDA to conduct clinical studies for CardiolRx™ in recurrent pericarditis and acute myocarditis [4]. - The MAVERIC Program addresses recurrent pericarditis, which can lead to severe symptoms and reduced quality of life, and includes a completed Phase II study and an ongoing Phase III trial [4]. - The ongoing ARCHER trial is a Phase II study focusing on acute myocarditis, a significant cause of heart failure and sudden cardiac death in young adults [4]. Additional Developments - Cardiol is also developing CRD-38, a novel subcutaneous formulation intended for heart failure treatment, which is a leading cause of death and hospitalization, with healthcare costs in the US exceeding $30 billion annually [5].

Exhibit 99.1 Oppenheimer Holdings Inc. Reports Fourth Quarter and Full Year 2024 Earnings New York, January 31, 2025 – Oppenheimer Holdings Inc. (NYSE: OPY) (the "Company" or "Firm") today reported net income of $10.7 million or $1.04 basic earnings per share for the fourth quarter of 2024 compared with net income of $11.1 million or $1.07 basic earnings per share for the fourth quarter of 2023. Fourth quarter and full year 2024 results were significantly impacted by higher pre-tax compensation expenses for ...

NEW YORK, Jan. 31, 2025 /PRNewswire/ - Oppenheimer Holdings Inc. (NYSE: OPY) (the "Company" or "Firm") today reported net income of $10.7 million or $1.04 basic earnings per share for the fourth quarter of 2024 compared with net income of $11.1 million or $1.07 basic earnings per share for the fourth quarter of 2023. Fourth quarter and full year 2024 results were significantly impacted by higher pre-tax compensation expenses for liability-based awards totaling $20.5 million and $32.6 million, respectively, ...

NervGen Pharma to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceJanuary 29, 2025 5:00 PM EST | Source: NervGen Pharma Corp.Vancouver, Canada--(Newsfile Corp. - January 29, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that Mr. Mike Kelly, President & CEO, will be participating in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences C ...

PLYMOUTH MEETING, Pa., Jan. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that Dr. Jacqueline Shea, INOVIO's President and CEO, and Dr. Michael Sumner, Chief Medical Officer, will be presenting at the Oppenheimer 35th Annual Healthcare Life Sciences Conference.Oppenheimer 35th Annual Healthcare Life Sciences Conference  ...

ENGLEWOOD, Colo., Jan. 14, 2025 /PRNewswire/ -- XTI Aerospace, Inc. (Nasdaq: XTIA) ("XTI Aerospace" or the "Company"), a pioneer in VTOL and Powered-Lift aircraft solutions, today announced that David Oppenheimer has joined the XTI Corporate Advisory Board.Mr. Oppenheimer is a seasoned professional with over 40 years of experience in advancing emerging technologies and national policy. He has led global research teams focused on advanced analog computing based on neural networking theories and optical displ ...

Key Investment Picks for 2025 - Olive Garden, KFC, and Shake Shack are identified as top investment picks for 2025 by Oppenheimer analysts [1] - Yum! Brands (YUM), Darden Restaurants (DRI), and Shake Shack (SHAK) received "top pick" distinctions in the 2025 restaurant outlook [1] Reasons for Selection - The trio stood out due to promising same-store sales forecasts, new leadership, and marketing efforts [2] - Yum! Brands is expected to rebound in 2025 after declining same-store sales in 2024, with growth anticipated across KFC's global portfolio and Taco Bell gaining market share [2] - Darden Restaurants is expected to see improved same-store sales as fine dining headwinds subside, with Olive Garden benefiting from food delivery and enhanced marketing [3] - Shake Shack's new CEO Rob Lynch is praised for improving restaurant efficiency and updating marketing strategies [4] Broader Industry Outlook - The restaurant industry is predicted to have a healthier 2025 after a decline in foot traffic in 2024, with recent order pickups indicating a positive trend [5] - Menu price hikes are expected to slow, with average price increases declining to 2% to 3% by the end of 2025, as ingredient, supply, and labor costs level off [5] - Staff turnover rates are at record lows, allowing restaurants to normalize menu-price increases and offer value without harming margins [6]

Core Insights - Oppenheimer & Co. Inc. is expanding its Fixed Income Division by hiring three new Managing Directors for its Emerging Markets Desk, indicating a strategic focus on enhancing capabilities in this area [1][5] Group 1: New Hires - Persio "Tony" Perez joins as EM Sales Manager, bringing nearly 30 years of experience, including roles at BCP Securities and Merrill Lynch, with a focus on hedge funds and asset managers [3] - Michael Chatman, with over 25 years of experience, joins from BCP Securities as EM Sales, having held positions at Barclay Investments and BNP Paribas, specializing in various debt products [4] - Bill Dolan, who has nearly 40 years of experience, comes from BCP Securities as EM Sovereign Trader, previously working at Salomon Brothers and Citigroup, with expertise in emerging markets trading [5] Group 2: Strategic Importance - The recruitment of these experienced professionals reflects Oppenheimer's commitment to strengthening its sales relationships, trading capabilities, and research products in emerging markets [2] - The new team members collectively possess long-term relationships and a deep understanding of the asset class, which will benefit clients investing in emerging markets [2]

Wealth Management Veteran Brings Over 25 Years of Industry ExperienceAppointment Builds on Firm's Momentum Created by Recent Appointments to Strengthen its Presence in Virginia, Georgia, Tennessee and Texas NEW YORK, Dec. 4, 2024 /PRNewswire/ -- Oppenheimer & Co. Inc. (Oppenheimer), a leading investment bank and wealth manager and a subsidiary of Oppenheimer Holdings (NYSE: OPY), today announced the appointment of Craig Schneider as Regional Director of its Michigan Region. Schneider will lead day-to-day op ...